Seeking oncology licensing opportunities.

Our Corporate Development team is actively engaged in exploring additional opportunities for strategic alliances that build on Threshold’s core capabilities and expertise in advancing innovative therapies to address unmet needs in oncology. Our preference is for targeted assets at the IND-enabling stage through early phase 2 with defined patient populations and best-in-class potential.

Eric meeting.jpg

Contact our corporate development team:
Eric Malek, Vice President, Corporate Development
bd@thresholdpharm.com